HLA-B
Immune System · HLA & Antigen Processing Presentation
Why does the exact HLA-B allele matter more than the gene name?
HLA-B helps present protein fragments to the immune system, and its many alleles differ in what they present. Disease or drug-response implications are tied to particular alleles and contexts rather than to HLA-B in general.
- Common Gene Name
- major histocompatibility complex, class I, B
- NCBI Gene ID
- 3106
- Chromosome
- 6
Clinical Evidence Status
Drug-response evidence availableTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (22 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| Ankylosing spondylitis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2022-03 | |
| Behçet disease | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2022-03 | |
| Psoriatic arthritis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2022-03 | |
| Juvenile idiopathic arthritis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2022-03 | |
| Stevens-Johnson syndrome/toxic epidermal necrolysis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2022-03 | |
| Shingles | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2022-03 | |
| Abacavir | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Carbamazepine | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Fosphenytoin | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Phenytoin | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Allopurinol | FDA pharmacogenetics | Potential safety or response effect | Drug-specific subgroup | View source |
| Oxcarbazepine | FDA pharmacogenetics | Potential safety or response effect | Drug-specific subgroup | View source |
| Pazopanib | FDA pharmacogenetics | Potential safety or response effect | Drug-specific subgroup | View source |
| Abacavir | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Infectious Diseases | View source |
| Allopurinol | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Cabotegravir and Rilpivirine (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Infectious Diseases | View source |
| Carbamazepine (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Neurology | View source |
| Fosphenytoin (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Neurology | View source |
| Oxcarbazepine | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Neurology | View source |
| Pazopanib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Phenytoin (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Neurology | View source |
| Lamotrigine | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Neurology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Immune System